Format

Send to

Choose Destination
Biol Blood Marrow Transplant. 2018 Aug;24(8):1537-1545. doi: 10.1016/j.bbmt.2018.03.021. Epub 2018 Mar 27.

Applications of Gene Editing Technologies to Cellular Therapies.

Author information

1
Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, North Carolina. Electronic address: lindsay.rein@duke.edu.
2
Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, North Carolina.

Abstract

Hematologic malignancies are characterized by genetic heterogeneity, making classic gene therapy with a goal of correcting 1 genetic defect ineffective in many of these diseases. Despite initial tribulations, gene therapy, as a field, has grown by leaps and bounds with the recent development of gene editing techniques including zinc finger nucleases, transcription activator-like effector nucleases, and clustered regularly interspaced short palindromic repeat (CRISPR) sequences and CRISPR-associated protein-9 (Cas9) nuclease or CRISPR/Cas9. These novel technologies have been applied to efficiently and specifically modify genetic information in target and effector cells. In particular, CRISPR/Cas9 technology has been applied to various hematologic malignancies and has also been used to modify and improve chimeric antigen receptor-modified T cells for the purpose of providing effective cellular therapies. Although gene editing is in its infancy in malignant hematologic diseases, there is much room for growth and application in the future.

KEYWORDS:

Cellular therapy; Gene editing

PMID:
29601858
DOI:
10.1016/j.bbmt.2018.03.021

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center